We sought to quantify the health impact of the new adult focus vaccine, V116 in comparison to PCV20 in adults.Table 1:Total IPD incidence per 100,000 (all ages) for each scenario at different time points. Also shown is the percent change from present values. METHODS. We developed a ...
The ACIP and CDC changed vaccination schedule especially for those age 65 and older. Instead of a single dose Polyscharide 23 vaccine, now PCV13 ( Prevnar) is the first one to be aplied this age group and 6 to 12 months later in adition to the PCV 13 a single dose PPSV23 vaccine ...
We speculate the rate of reduction and time to stabilization of IPD incidence across age groups and countries may be associated with multiple factors including vaccine schedule, implementation of a catch-up program, duration of PCV7 use, vaccine uptake, availability of an adult program, serotypes ...
Progress in introduction of pneumococcal conjugate vaccine - worldwide, 2000-2012. added PCV to the routine infant immunization schedule of their national immunization programs; among those, 23 have introduced PCV with GAVI Alliance support... SA Wang,CF Mantel,M Gacic,... - 《Mmwr Morb Mortal...
Year of PCV7 introduction (vaccine schedule†) 2009 (3 + 1, with catch-up) 2009 (2 + 1, with catch-up) No PCV7 introduction 2009 (2 + 1, without catch-up) 2009 (3 + 0, without catch-up) 2000 (3 + 1, with catch-up) Year of PCV10 or PCV13 introd...
Infection with Streptococcus pneumoniae is a life-threatening, but vaccine preventable complication in patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT). The international consensus on post allo-HSCT immunization schedules, starting 3-6 months after HSCT, focuses on short-term...
There is potential to change the current 3+0 schedule of PCV13 in Malawi after studies found lower herd protection effects than expected [2]. One proposal to improve this, based on potential wan- ing effects of the 3+0 vaccine schedule with age, is a 2+1 schedule with two doses in ...
Our overall objective was therefore to evaluate safety and immunogenicity of a combination PCV schedule of PHiD-CV10 (S) given at 1–2–4 months plus PCV13 (P) given at 6 months (SSSP) compared to either vaccine alone when given at 2–4-6 months (_SSS or _PPP). The aim being to...
In Portugal, the 13-valent pneumococcal conjugate vaccine (PCV13) was commercially available between 2010 and 2015, following a decade of private use of PCV7. We evaluated changes on serotype distribution and antimicrobial susceptibility of pneumococci carried by children living in two regions of Por...
Pneumococcal conjugate vaccines (PCV) have reduced invasive pneumococcal disease (IPD) (see other PSERENADE abstract), of which > 70% was vaccine-type pre-PCV. We described the serotype (ST) distribution of remaining IPD in countries with mature infant PCV10/13 programs. METHODS. IPD ST ...